Skip to main content

Table 2 Patients’ characteristics

From: Ageing-resembling phenotype of long-term allogeneic hematopoietic cells recipients compared to their donors

Patient no.

Diagnosis

Sex (R/D)

Time since allo-HCT (years)

Age at allo-HCT (years)

R/D

Conditioning regimen

Chronic GvHD *

Infection risk status (low, high) **

Number of CD34+cells infused (x 10^6/kg)

1

CML

M/F

25

33/27

BuCy

-

Low

-

2

ALL

F/M

18

20/15

TBI

-

High

7,78

3

AML

M/M

15

23/25

BuCy

-

Low

6,3

4

AML

F/M

20

36/46

BuCy

Yes

Low

11,6

5

HES

M/F

19

32/33

BuCy

-

Low

1,56

6

CML

M/M

18

46/43

BuCy

-

Low

5,6

7

CML

F/F

17

22/10

BuCy

Yes

Low

-

8

PNH

M/M

18

27/20

BuCy

-

Low

1,31

9

CML

M/F

23

39/41

BuCy

Yes

High

-

10

AML

M/F

14

43/39

BuCy

Yes

High

-

11

AML

F/F

17

47/43

BuCy

Yes

High

-

12

CML

M/M

19

36/18

BuCy

-

High

3,4

13

ALL

F/M

24

28/24

BuCy

-

Low

-

14

AML

M/F

15

31/28

BuCy

-

Low

3,9

15

CML

M/M

20

44/43

BuCy

-

Low

8

16

MDS

F/F

12

42/43

BuCy

Yes

High

1,94

17

CML

F/M

17

38/43

BuCy

-

High

1,35

18

AML

F/M

12

38/38

BuCy

Yes

Low

6,06

19

CML

M/M

13

33/22

BuCy

Yes

High

-

20

AML

M/F

12

41/54

BuCy

-

Low

0,88

  1. * History of chronic cGvHD
  2. ** Status assessment according to Table 1
  3. (CML – chronic myelogenous leukemia, ALL – acute lymphoblastic leukemia, AML – acute myelogenous leukemia, HES – hypereosinophilic syndrome, PNH – paroxysmal nocturnal hemoglobinuria, MDS – myelodysplastic syndrome, R – recipient, D – donor, MRD – matched related donor, MUD – matched unrelated donor, BuCy – busulfan & cyclophosphamide, TBI – total body irradiation)